The Helsana Group is the leading health and accident insurer in Switzerland. It offers individuals and companies a complete health and prevention service in the event of sickness and accidents.
Greater transparency in the supply of medicinal products
The 2017 Drug Report follows on from previous versions, and offers analyses of biologics and biosimilar generic drugs, as well as medication in Swiss nursing homes, in addition to its general section. With its report, Helsana is ensuring greater transparency in the healthcare sector, and thus helping to improve the care that our customers receive.
The Swiss healthcare system is characterised by a high level of innovation. This includes new and further developments in the pharmaceutical industry. Development work also increases the cost of medication, however. In 2016, spending on prescription drugs covered by basic insurance rose by around six per cent year on year – to more than CHF 7 billion, corresponding to around a quarter of basic health insurance costs overall.
The Drug Report is intended to contribute to a better understanding of the Swiss medication market, and of how volumes and costs have developed in recent years. At the same time, it should stimulate an objective discussion about the sensible and responsible use of prescription drugs.
Unique in Switzerland
The Helsana Drug Report is unique in Switzerland. The report – compiled in cooperation with the University Hospital of Basel (USB) and the European Centre of Pharmaceutical Medicine (ECPM) at the University of Basel – provides authentic insights into the supply of medicinal products in Switzerland. We also cast a critical eye on the market for medicinal products, look for anomalies and differences, and identify room for improvement. We do so from the perspective of our customers and in our role as the "trustee" of Swiss premium payers.
Transparency takes centre stage
The report contains assessments of market trends based on our own (anonymised) statement data and provides a representative picture of the number of recipients of medication and the resulting costs. We also provide an in-depth analysis of selected indications and medication groups. The focus falls on the transparent representation of real trends.